NCT04820179View on ClinicalTrials.gov

Atezolizumab + Cabozantinib in Patients w/ Metastatic, Refractory Pancreatic Cancer

PHASE2RecruitingINTERVENTIONAL
Enrollment

29

Participants

Timeline

Start Date

October 12, 2021

Primary Completion Date

October 31, 2025

Study Completion Date

October 31, 2025

Conditions
Pancreatic CancerMetastatic Pancreatic Cancer
Interventions
DRUG

Cabozantinib + Atezolizumab

All the subjects will be treated with the combination of cabozantinib and atezolizumab until disease progression, unacceptable toxicity or patient consent withdrawal (whichever occurs first).

Trial Locations (1)

85724

RECRUITING

University of Arizona Cancer Center, Tucson

All Listed Sponsors
lead

University of Arizona

OTHER